The weight-loss medication Ozempic and Wegovy, while effective for many, may pose a hidden danger for individuals with neurodegenerative conditions like ALS. Neurologists, including Jinsy Andrews, MD, caution that the rapid weight loss these drugs induce can exacerbate the already challenging biological needs of patients with neuromuscular disorders. The very mechanism that makes these drugs popular—rapid weight loss—can be detrimental to those with ALS, as it can accelerate physical decline and worsen symptoms. This is particularly concerning given that standard clinical care guidelines for ALS often recommend maintaining or even gaining weight to preserve nerve and muscle function. A 2025 case report published in the medical journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration highlights the potential risks. A 52-year-old ALS patient prescribed semaglutide for diabetes experienced a 25-pound weight loss in three months, leading to a sudden and dramatic worsening of her disease trajectory. Discontinuing the medication stabilized her physical decline. This case, along with retrospective cohort data, underscores the need for clinicians to carefully consider the use of GLP-1 receptor agonists in ALS patients, especially those with diabetes. While these medications offer significant benefits, maintaining body weight and muscle mass is crucial for individuals with neurodegenerative diseases. Patient safety is a priority for manufacturers like Novo Nordisk, who emphasize that ALS is not listed as an adverse reaction in the prescribing information for their products. However, the potential risks for those with neurodegenerative conditions cannot be overlooked, and further research is necessary to ensure the safe and effective use of these weight-loss medications.
